CT 7439
Alternative Names: CT-7439Latest Information Update: 04 Jul 2025
At a glance
- Originator Carrick Therapeutics
- Class Antineoplastics
- Mechanism of Action CDK13 protein inhibitors; Cyclin dependent kinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 16 Aug 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT06600789)
- 16 Aug 2024 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT06600789)